Filing Analysis
Atossa Therapeutics, Inc. filed an 8-K to announce its second quarter financial results for the period ended June 30, 2026. The filing serves as a formal announcement of the company's quarterly earnings and operational update.
📋 Key Facts
- Report date: August 7, 2026
- Reporting period: Second quarter ended June 30, 2026
- The filing includes an earnings press release as Exhibit 99.1
- Company is listed on the Nasdaq Capital Market under ticker ATOS
Atossa Therapeutics entered into a securities purchase agreement on June 10, 2026, for a registered direct offering of 1,363,638 shares of common stock and associated Series A and B warrants. The company expects to raise approximately $4.1 million in net proceeds to fund clinical development and working capital.
🚩 Red Flags
- Dilution: The issuance of over 1.3 million shares plus significant warrant coverage (Series A, B, and Placement Agent warrants) increases the potential share count significantly.
📋 Key Facts
- Offering price is $3.30 per share combined with Series Warrants.
- Issuance of 1,363,638 shares of common stock.
- Issuance of Series A and Series B warrants to purchase up to 1,363,638 shares each with an exercise price of $4.40.
- Expected net proceeds of approximately $4.1 million.
- Potential additional gross proceeds of ~$12 million if warrants are fully exercised on a cash basis.
- Placement agent Rodman & Renshaw LLC receives a 7.0% cash fee and warrants for ~123,000 shares at $4.125 per share.
Atossa Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026. The filing includes a press release providing a general company update and summary of financial performance.
📋 Key Facts
- The company announced financial results for the quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release dated May 8, 2026, was included as Exhibit 99.1.
- The filing was signed by Mark J. Daniel, Chief Financial Officer.
Atossa Therapeutics stockholders approved a potential reverse stock split at its 2026 Annual Meeting with a ratio ranging from 2:1 to 20:1. The meeting also resulted in the re-election of three directors and the ratification of Ernst & Young LLP as the company's independent auditor.
🚩 Red Flags
- Approval of a reverse stock split, which is frequently a defensive measure to maintain Nasdaq listing compliance due to a low share price.
- Significant shareholder opposition to the reverse split, with approximately 44% of voted shares (excluding abstentions) voting against the proposal.
📋 Key Facts
- Annual Meeting of Stockholders held on May 7, 2026.
- Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 2:1 and 20:1.
- The reverse split proposal received 2,336,815 votes 'For' and 1,866,873 votes 'Against'.
- Ernst & Young LLP was ratified as the independent auditor for the fiscal year ending December 31, 2026.
- Three Class II directors (Stephen J. Galli, Richard I. Steinhart, and Tessa Cigler) were elected to the board.
Atossa Therapeutics entered into a settlement agreement with Intas Pharmaceuticals and Jina Pharmaceuticals to resolve patent disputes and PTAB proceedings regarding its Endoxifen-related intellectual property. The agreement preserves Atossa's rights to develop Z-endoxifen in its core therapeutic areas while establishing field allocations and mutual non-challenge covenants.
📋 Key Facts
- Settlement Agreement entered into on April 13, 2026, with Intas Pharmaceuticals Ltd. and Jina Pharmaceuticals, Inc.
- Resolves challenges to U.S. Patents Nos. 11,261,151 and 12,071,391 titled 'Methods for Making and Using Endoxifen'.
- The parties have agreed to seek termination of pending proceedings before the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB).
- Atossa retains the ability to develop and commercialize Z-endoxifen base in oncology, endocrine dysfunction disorders, and muscular dystrophy-related diseases.
- The agreement includes mutual covenants not to challenge specified Endoxifen-related patents and patent applications owned by the other parties.
Atossa Therapeutics, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The filing includes a press release providing a general company update alongside the financial data.
📋 Key Facts
- Reported Q4 and full-year 2025 financial results on March 25, 2026
- The filing includes Exhibit 99.1, a press release with financial details and a company update
- The information is furnished under Item 2.02 and is not deemed 'filed' for Section 18 purposes
Atossa Therapeutics (ATOS) entered into a new $50 million at-the-market (ATM) equity offering agreement with Rodman & Renshaw LLC on February 20, 2026, while simultaneously terminating its prior ATM agreement with Jefferies LLC (under which no shares were ever sold). The proceeds are earmarked for clinical development, working capital, and general corporate purposes.
🚩 Red Flags
- $50M ATM offering represents significant potential dilution for a micro-cap biotech — investors should compare against current market cap and cash runway
- Switch from Jefferies (a larger, more established agent) to Rodman & Renshaw (a smaller boutique) may signal difficulty maintaining relationships with larger banks or reflect the company's micro-cap status
- No shares sold under prior Jefferies ATM despite having it in place since November 2024, yet immediate replacement with a new ATM suggests potential near-term capital needs
- Multiple 8-K items filed simultaneously (1.01 and 1.02) indicating structural change in capital markets strategy
- Vague use-of-proceeds language ('may also use a portion to license, acquire or invest') provides management wide discretion
📋 Key Facts
- New ATM offering agreement with Rodman & Renshaw LLC for up to $50,000,000 in common stock sales
- Sales agent commission of up to 3.0% of gross proceeds
- Prior ATM agreement with Jefferies LLC (dated November 19, 2024) terminated effective February 19, 2026 with no termination penalties
- No shares were sold under the prior Jefferies agreement
- Proceeds intended for clinical development of product candidates, working capital, and general corporate purposes
- Registration Statement on Form S-3 (File No. 333-279367) filed May 13, 2024, declared effective May 23, 2024
- Company listed on Nasdaq Capital Market; common stock par value $0.18/share
- Filed February 20, 2026; earliest event date February 19, 2026
- Legal counsel: Gibson, Dunn & Crutcher LLP
- Signed by CFO Mark J. Daniel
Atossa Therapeutics, Inc. has successfully regained compliance with Nasdaq's minimum closing bid price requirement of $1.00 per share. The company met the necessary 10-consecutive trading day threshold as of February 13, 2026, avoiding delisting.
🚩 Red Flags
- History of non-compliance with minimum bid price requirements (dating back to February 2025).
📋 Key Facts
- Received notice from Nasdaq on February 17, 2026, confirming compliance with Listing Rule 5550(a)(2).
- The company failed to maintain a $1.00 minimum bid price starting around February 21, 2025.
- Compliance was achieved by maintaining the $1.00 threshold for at least 10 consecutive trading days as of Feb 13, 2026.
- The company had previously been granted a 180-day extension to regain compliance.
Atossa Therapeutics, Inc. filed an 8-K to furnish its 2026 Letter to Shareholders via a press release under Item 7.01 (Regulation FD Disclosure). The filing does not contain new material business developments or financial changes.
📋 Key Facts
- The company issued its 2026 Letter to Shareholders on February 11, 2026.
- Information was furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
- The filing includes Exhibit 99.1 containing the press release.
Atossa Therapeutics, Inc. held a special meeting on January 20, 2026, where stockholders approved a reverse stock split of common stock. The split will be executed at a ratio of 15:1 and is expected to become effective on February 2, 2026.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq compliance or mitigate low share price)
- Significant dilution/concentration of shares via the 15:1 ratio
📋 Key Facts
- Reverse stock split ratio: 15:1
- Effective time: 12:01 a.m. ET on February 2, 2026
- New CUSIP number: 04962H704
- The company will pay cash in lieu of fractional shares based on the closing price on January 30, 2026
- Stockholders approved a range of 5:1 to 20:1; the Board selected 15:1
- Trading under symbol 'ATOS' on Nasdaq will continue on a split-adjusted basis
Atossa Therapeutics released an updated corporate presentation providing a preliminary estimate of its financial position. The company reported approximately $40 million in cash and cash equivalents as of December 31, 2025.
🚩 Red Flags
- Financial data provided is preliminary and unaudited, requiring caution regarding reliance on these figures.
📋 Key Facts
- Estimated cash and cash equivalents: ~$40 million as of Dec 31, 2025.
- The financial figures provided are preliminary, unaudited, and subject to finalization.
- The filing includes an updated corporate presentation (Exhibit 99.1).
- Company is focused on the development/regulatory strategy for (Z)-Endoxifen.
Atossa Therapeutics, Inc. announced that the FDA has issued a 'Study May Proceed' letter for its clinical study targeting metastatic breast cancer.
📋 Key Facts
- FDA issued a 'Study May Proceed' letter on January 6, 2026.
- The regulatory clearance pertains to the Company's study of metastatic breast cancer.
- A press release was issued simultaneously as Exhibit 99.1.
Atossa Therapeutics, Inc. announced the completion of a Type C meeting with the FDA on November 17, 2025. The meeting focused on discussing regulatory strategies and development pathways for (Z)-endoxifen across various breast cancer indications.
📋 Key Facts
- Type C meeting held with the FDA on November 17, 2025.
- Discussion centered on regulatory strategy for advancing (Z)-endoxifen.
- FDA feedback covered metastatic disease, neoadjuvant treatment, and breast cancer risk-reduction settings.
Atossa Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ended September 30, 2025. The filing serves as a formal announcement of the earnings release and company update.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and a company update.
- Signed by Mark J. Daniel, Chief Financial Officer.
Atossa Therapeutics announced the immediate appointment of Mark Daniel as CFO and Principal Accounting Officer, succeeding Heather Rees. Ms. Rees will remain as a non-officer employee through mid-November 2025 to facilitate the transition.
🚩 Red Flags
- Immediate departure of the CFO/PAO can sometimes signal internal friction or rapid shifts in financial strategy.
- Significant severance package (9 months salary) for the outgoing CFO.
📋 Key Facts
- Mark Daniel appointed CFO and PAO effective October 14, 2025.
- Heather Rees departed her role as CFO/PAO on October 14, 2025; remains an employee until November 15, 2025.
- Ms. Rees's separation agreement includes nine months of base salary and COBRA premiums in exchange for a release of claims.
- Mr. Daniel's compensation includes a $415,900 base salary and a target annual bonus of up to 40% starting in FY2026.
- Mr. Daniel was granted stock options for 578,000 shares of common stock under the 2020 Stock Incentive Plan.
Atossa Therapeutics, Inc. filed an 8-K to provide an updated corporate presentation via Item 7.01 Regulation FD Disclosure.
📋 Key Facts
- The filing was made on September 26, 2025.
- The company released an updated corporate presentation (Exhibit 99.1).
- Information is provided under Item 7.01 for Regulation FD purposes and is not considered 'filed' for liability purposes under Section 18 of the Exchange Act.
Atossa Therapeutics announced a new regulatory strategy intended to accelerate the development of low-dose (Z)-endoxifen for breast cancer risk reduction. This is a strategic update regarding their clinical/regulatory pathway rather than a financial or structural event.
📋 Key Facts
- Company announced a new regulatory strategy on September 8, 2025.
- The strategy focuses on accelerating the development of low-dose (Z)-endoxifen.
- Target indication is breast cancer risk reduction.
Atossa Therapeutics received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company's initial compliance period expired on August 20, 2025, and it must maintain a $1.00 closing bid price by February 17, 2026.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq minimum bid price requirement.
- Explicit mention of potentially effectuating a reverse stock split (Red flag escalator).
- Failure to maintain $1.00 share price for 30 consecutive business days.
📋 Key Facts
- Received notice from Nasdaq regarding non-compliance with Rule 5550(a)(2) (minimum $1.00 bid price).
- Initial compliance period ended on August 20, 2025.
- Nasdaq granted a 180-day extension to regain compliance.
- New deadline for compliance is February 17, 2026.
- The company explicitly mentioned the possibility of a reverse stock split to meet requirements.
Atossa Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter ended June 30, 2025, and provided a general company update via press release.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes an announcement of financial results and a corporate update via Exhibit 99.1.
Atossa Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ended March 31, 2025, and provided a general company update via press release.
📋 Key Facts
- Report date: May 13, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes an announcement of financial results and a company update (Exhibit 99.1).
- The information in Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Atossa Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on May 8, 2025. The meeting resulted in the election of two Class I directors and the ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025.
📋 Key Facts
- Annual Meeting held on May 8, 2025.
- Steven C. Quay, M.D., Ph.D. and Jonathan F. Finn, C.F.A. were elected as Class I directors.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Stockholders approved advisory votes on executive compensation (Say-on-Pay) and determined a one-year frequency for future such votes.
- Record date for the meeting was March 20, 2025, with 129,170,004 shares entitled to vote.
Atossa Therapeutics announced that Intas Pharmaceuticals Ltd. has filed Petitions for Post Grant Review (PGR) and Inter Partes Review (IPR) against two of the Company's patents related to 'Methods for Making and Using Endoxifen'. The company intends to contest these filings but acknowledges there is no guarantee of success.
🚩 Red Flags
- Intellectual property litigation/challenges directly threaten the exclusivity of core product assets (Endoxifen).
- Uncertainty regarding patent validity could impact future revenue streams and market exclusivity.
📋 Key Facts
- Intas Pharmaceuticals Ltd. filed a PGR Petition regarding U.S. Patent No. 12,071,391 on April 7, 2025.
- Intas Pharmaceuticals Ltd. filed an IPR Petition regarding U.S. Patent No. 11,261,151 on April 7, 2025.
- Both patents relate to 'Methods for Making and Using Endoxifen'.
- The Company intends to vigorously contest both petitions.
Atossa Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024, and provided a general company update via press release.
📋 Key Facts
- Report date: March 25, 2025
- Reporting period: Year ended December 31, 2024
- The filing includes an announcement of financial results and a corporate update (Exhibit 99.1).
- Filed by CFO Heather Rees.
Atossa Therapeutics announced a strategic decision to pursue the metastatic breast cancer indication for its candidate (Z)-endoxifen. The company is also continuing discussions with the FDA regarding additional therapeutic indications.
📋 Key Facts
- Strategic pivot/focus: Pursuing metastatic breast cancer indication for (Z)-endoxifen.
- Ongoing regulatory engagement: Continued discussions with the FDA regarding other potential indications.
- Filing date of event: March 11, 2025.
Atossa Therapeutics, Inc. received a notice from Nasdaq informing the company it is non-compliant with the minimum bid price requirement of $1.00 per share. The company has until August 20, 2025, to regain compliance or seek an extension.
🚩 Red Flags
- Delisting notice regarding minimum bid price requirement
- Stock price has been trading below the $1.00 threshold for an extended period
📋 Key Facts
- Received notice from Nasdaq on February 21, 2025.
- Non-compliance due to failure to maintain a minimum closing bid price of $1.00 for 30 consecutive business days (Nasdaq Listing Rule 5550(a)(2)).
- Deadline to regain compliance is August 20, 2025.
- A potential 180-day extension may be available if the deadline is not met.
- To regain compliance, stock must close at $1.00 or higher for 10 consecutive business days.
Atossa Therapeutics announced a significant adverse legal ruling where the PTAB found all claims under U.S. Patent No. 11,572,334 to be unpatentable. The company has decided not to appeal this decision due to cost and time constraints.
🚩 Red Flags
- Loss of patent protection for a key asset (U.S. Patent No. 11,572,334) significantly weakens intellectual property moat.
- Decision not to appeal indicates a strategic retreat from defending existing IP in this specific instance.
📋 Key Facts
- PTAB final written decision in PGR2023-00043 found all claims under U.S. Patent No. 11,572,334 unpatentable.
- Company will not pursue an appeal of the PTAB decision due to cost and time considerations.
- Company has filed a new Continuation Patent Application with the U.S. Patent Office to protect current formulations in clinical development.
- The company was issued a new patent on January 21, 2025 (U.S. Patent No. 12,201,591) regarding 'Sustained Release Compositions of Endoxifen'.
- The core focus remains the (Z)-endoxifen program for breast cancer prevention and treatment.
Atossa Therapeutics, Inc. issued an 8-K to announce the presentation of three posters at the San Antonio Breast Cancer Symposium. These posters contain pharmacokinetic and tolerability data from the company's Phase 2 EVANGELINE trial.
📋 Key Facts
- Date of event: December 10, 2024
- Event: Presentation of three scientific posters at the San Antonio Breast Cancer Symposium
- Data content: Pharmacokinetic and tolerability data from the Phase 2 EVANGELINE trial
- Exhibit 99.1 contains the full press release regarding these clinical updates
Atossa Therapeutics entered into an Open Market Sale Agreement with Jefferies LLC to facilitate the potential sale of up to $100,000,000 of common stock via an 'at-the-market' (ATM) offering. The proceeds are intended for clinical development, working capital, and general corporate purposes.
🚩 Red Flags
- Significant dilution risk: The $100M ceiling represents a large potential increase in share supply which can depress stock price during the offering period.
- ATM offerings are often used by micro-cap biotech companies to fund ongoing burn rates, signaling continuous need for external capital.
📋 Key Facts
- Entered into Open Market Sale Agreement with Jefferies LLC on November 19, 2024.
- Maximum aggregate sale amount of $100,000,000 in common stock.
- Offering is an 'at-the-market' (ATM) type under Rule 415(a)(4).
- Sales Agent (Jefferies LLC) to receive a commission of up to 3.0% of gross proceeds.
- Proceeds intended for clinical development, working capital, and potential acquisitions/licensing.
Atossa Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ended September 30, 2024, and provided a general company update via press release.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes an announcement of financial results and a corporate update (Exhibit 99.1).
Atossa Therapeutics announced positive topline data from its KARISMA-Endoxifen Phase 2 study. The study evaluated (Z)-endoxifen in premenopausal women with mammographic breast density (MBD).
📋 Key Facts
- Announced positive topline results from the KARISMA-Endoxifen Phase 2 study.
- Study focus: (Z)-endoxifen in premenopausal women with mammographic breast density (MBD).
- Data released via press release on November 4, 2024.
Atossa Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ended June 30, 2024 and provided a general company update via press release.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes the announcement of financial results and a company update (Exhibit 99.1).
Atossa Therapeutics held its 2024 Annual Meeting of Stockholders on June 27, 2024. The meeting resulted in the election of two directors, ratification of Ernst & Young LLP as independent auditors, and approval of several key corporate amendments including a significant increase in authorized shares.
🚩 Red Flags
- Significant increase in authorized shares (from 175M to 350M) which can lead to future dilution for existing shareholders.
📋 Key Facts
- Annual Meeting held on June 27, 2024.
- Stockholders approved an amendment to the 2020 Stock Incentive Plan, increasing available shares by 12,000,000.
- Heather Rees appointed as Chief Financial Officer (CFO), effective immediately; her base salary is set at $439,700 with a 40% target cash bonus.
- Stockholders approved an amendment to the Certificate of Incorporation to increase authorized Common Stock from 175,000,000 to 350,000,000 shares.
- Ernst & Young LLP was ratified as independent auditors for fiscal year ending Dec 31, 2024.
- Shu-Chih Chen and H. Lawrence Remmel were elected as Class III directors.
Atossa Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ended March 31, 2024 and provided a general company update via press release.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes an announcement of financial results and a company update (Exhibit 99.1).
Atossa Therapeutics filed an 8-K/A to amend a previous filing from April 1, 2024. The amendment is intended to correct clerical errors in the Consolidated Statements of Operations previously released in their year-end 2023 financial results press release.
🚩 Red Flags
- Restatement/Correction of previously issued financial information (even if categorized as clerical) can signal internal control weaknesses in financial reporting.
📋 Key Facts
- The filing is an Amendment (8-K/A) to a report filed on April 1, 2024.
- Errors were identified in the Consolidated Statements of Operations for the year ended December 31, 2023.
- The errors are characterized as 'clerical errors' within the press release issued alongside the financial results.
- A corrected version of the press release is provided as Exhibit 99.1.
Atossa Therapeutics, Inc. filed an 8-K to announce its year-ended December 31, 2023 financial results and provide a corporate update via press release.
📋 Key Facts
- Report date: April 1, 2024
- The filing announces the release of full-year 2023 financial results.
- Includes a company update alongside the earnings announcement.
Atossa Therapeutics has successfully regained compliance with Nasdaq's minimum closing bid price requirement. The company met the necessary 10-consecutive-trading-day threshold on March 14, 2024.
🚩 Red Flags
- Historical non-compliance with minimum bid price requirements (a sign of extreme volatility or low share price pressure).
📋 Key Facts
- Nasdaq notified the Company on March 15, 2024, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2).
- The company was previously non-compliant due to failing to maintain a $1.00 minimum closing bid price for 30 consecutive business days.
- Compliance was achieved by maintaining a minimum closing bid price of $1.00 per share for at least 10 consecutive trading days, ending March 14, 2024.
- The common stock will continue to be listed and traded on The Nasdaq Capital Market.
Atossa Therapeutics, Inc. announced the appointment of Dr. Tessa Cigler, M.D., M.P.H., to its Board of Directors as a Class II director and member of the Nominating and Governance Committee, effective March 9, 2024.
📋 Key Facts
- Dr. Tessa Cigler appointed as Class II director effective March 9, 2024.
- Term to last until the 2026 Annual Meeting of Stockholders or until a successor is elected.
- Appointed to the Nominating and Governance Committee.
- Compensation will follow the terms described in the Company’s Proxy Statement filed March 30, 2023.
- Dr. Cigler has an extensive background in medical oncology and clinical investigation at Weill Cornell Breast Center.